Evidence map›Paper›PMID 28250048›Full record

ReviewDisease models & mechanisms2017

MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications.

Ashlee M Strubberg, Blair B Madison

Open access · goldAbstract readReview
In one paragraph

Review in Disease models & mechanisms, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 3 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 3 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.International journal of molecular sciences · 2025
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ashlee M StrubbergDivision of Gastroenterology, Washington University School of Medicine, Washington University, Saint Louis, MO 63110, USA.
Blair B MadisonDivision of Gastroenterology, Washington University School of Medicine, Washington University, Saint Louis, MO 63110, USA bmadison@wustl.edu.ORCID 0000-0001-7457-1832
Washington University in St. Louis · US

Funding

Washington University DDRCC Supplemental Equipment RequestP30DK052574 · NIDDK · WASHINGTON UNIVERSITY · PI Nicholas O. Davidson · 2000 to 2026
$30.8M
Role of LIN28B in the regulation of intestinal epithelial growthK01DK093885 · NIDDK · WASHINGTON UNIVERSITY · PI MADISON, BLAIR BERNARD · 2012 to 2016
$647k
LET-7 MICRORNA REPRESSION OF STEM CELL COMPETITION AND CLONAL EXPANSIONR03DK108764 · NIDDK · WASHINGTON UNIVERSITY · PI MADISON, BLAIR BERNARD · 2016 to 2017
$153k
NIDDK NIH HHS K01 DK093885NIDDK NIH HHS P30 DK052574NIDDK NIH HHS R03 DK108764
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are small single-stranded RNAs that repress mRNA translation and trigger mRNA degradation. Of the ∼1900 miRNA-encoding genes present in the human genome, ∼250 miRNAs are reported to have changes in abundance or altered functions in colorectal cancer. Thousands of studies have documented aberrant miRNA levels in colorectal cancer, with some miRNAs reported to actively regulate tumorigenesis. A recurrent phenomenon with miRNAs is their frequent participation in feedback loops, which probably serve to reinforce or magnify biological outcomes to manifest a particular cellular phenotype. Here, we review the roles of oncogenic miRNAs (oncomiRs), tumor suppressive miRNAs (anti-oncomiRs) and miRNA regulators in colorectal cancer. Given their stability in patient-derived samples and ease of detection with standard and novel techniques, we also discuss the potential use of miRNAs as biomarkers in the diagnosis of colorectal cancer and as prognostic indicators of this disease. MiRNAs also represent attractive candidates for targeted therapies because their function can be manipulated through the use of synthetic antagonists and miRNA mimics.

Indexed as

AnimalsCarcinogenesisColorectal NeoplasmsGenetic PleiotropyHumansMicroRNAsNeoplastic Stem CellsSignal TransductionMicroRNAsCancerColonColorectalmicroRNARectalTumorigenesis

Identifiers

PMID28250048
PMCPMC5374322
OpenAlexW2594158458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.